Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for Corcept Therapeutics (CORT) over the last 10 years, with Q3 2025 value amounting to $0.16.

  • Corcept Therapeutics' EPS (Weighted Average and Diluted) fell 6097.56% to $0.16 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.87, marking a year-over-year decrease of 3095.24%. This contributed to the annual value of $1.23 for FY2024, which is 3099.41% up from last year.
  • Corcept Therapeutics' EPS (Weighted Average and Diluted) amounted to $0.16 in Q3 2025, which was down 6097.56% from $0.29 recorded in Q2 2025.
  • Over the past 5 years, Corcept Therapeutics' EPS (Weighted Average and Diluted) peaked at $0.41 during Q3 2024, and registered a low of $0.14 during Q4 2022.
  • Its 5-year average for EPS (Weighted Average and Diluted) is $0.24, with a median of $0.25 in 2023.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first skyrocketed by 10000.0% in 2023, then plummeted by 6097.56% in 2025.
  • Over the past 5 years, Corcept Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at $0.26 in 2021, then crashed by 46.15% to $0.14 in 2022, then skyrocketed by 100.0% to $0.28 in 2023, then fell by 4.36% to $0.27 in 2024, then tumbled by 40.25% to $0.16 in 2025.
  • Its last three reported values are $0.16 in Q3 2025, $0.29 for Q2 2025, and $0.17 during Q1 2025.